This post was originally published on this site
Investing.com – Moderna (NASDAQ:MRNA) and BioNTech stocks (NASDAQ:BNTX) slumped by 15% each Wednesday on a report that Europe’s drug regulator is studying three new conditions reported by a small number of people after vaccination with Covid-19 shots to assess if they may be possible side-effects.
The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.
Pfizer stock fell 3%. Expenses and profit from the Covid vaccine are split equally between Pfizer (NYSE:PFE) and BioNTech.
BioNTech-Pfizer is the biggest supplier of Covid-19 vaccines to Europe.
Just over 43.5 million doses of Moderna’s vaccine have been administered in the European Economic Area as of July 29, the EMA said, compared to more than 330 million doses of the BioNTech-Pfizer shot.
